Seattle Genetics Overview

  • Founded
  • 1997
Founded
  • Status
  • Public
  • Employees
  • 1,605
Employees
  • Stock Symbol
  • SGEN
Stock Symbol
  • Investments
  • 4
  • Share Price
  • $190.80
  • (As of Wednesday Closing)

Seattle Genetics General Information

Description

Seagen Inc is a biotech firm focused on developing antibody-drug conjugates. The company's lead product, Adcetris, has received approval for advanced front-line, relapsed/refractory and post-consolidation Hodgkin lymphoma, anaplastic large-cell lymphoma, and two other subtypes of cutaneous T-cell lymphoma. Other approved products include Padcev (bladder cancer) and Tukysa (breast cancer). The company has several other oncology programs in pivotal trials. Seagen also licenses its antibody-drug conjugate technology to a number of leading biotechnology and pharmaceutical companies.

Contact Information

Website
Ownership Status
Publicly Held
Financing Status
Formerly VC-backed
Primary Industry
Drug Discovery
Other Industries
Pharmaceuticals
Biotechnology
Stock Exchange
NAS
Primary Office
  • 30th Drive Southeast
  • Suite 21823
  • Bothell, WA 98021
  • United States
+1 (425) 000-0000
Want detailed data on 3M+ companies?

What you see here scratches the surface

Request a free trial
Want to dig into this profile?

We’ll help you find what you need

Learn more

Seattle Genetics Stock Performance

(As of Wednesday Closing)

Stock Price Previous Close 52 wk Range Market Cap Shares Average Volume EPS
$190.80 $188.78 $90.57 - $213.94 $34.2B 179M 940K $2.73

Seattle Genetics Financials Summary

In Thousands,
USD
TTM 30-Sep-2020 FY 2019 31-Dec-2019 FY 2018 31-Dec-2018 FY 2017 31-Dec-2017
EV 33,217,394 18,790,185 8,610,790 7,243,062
Revenue 1,864,047 916,713 654,700 482,250
EBITDA 528,713 (125,136) (220,314) (134,618)
Net Income 472,405 (158,650) (222,693) (125,530)
Total Assets 3,004,961 2,205,866 1,503,329 877,949
Total Debt 65,003 77,052 0
Public Fundamental Data provided by Morningstar, Inc. disclaimer

Seattle Genetics Valuation & Funding

Deal Type Date Amount Valuation/
EBITDA
Post-Val Status Debt

This information is available in the PitchBook Platform. To explore Seattle Genetics‘s full profile, request access.

Request a free trial

Seattle Genetics Cap Table

Stock # of Shares
Authorized
Par Value Dividend Rate (%) Original
Issue Price
Liquidation Liquidation
Pref. Multiple
Conversion
Price
% Owned

This information is available in the PitchBook Platform. To explore Seattle Genetics‘s full profile, request access.

Request a free trial

Seattle Genetics Comparisons

Description
Primary
Industry
HQ Location
Employees
Total Raised
Post Valuation
Last Financing Details
Seagen Inc is a biotech firm focused on developing antibody-drug conjugates. The company's lead product, Adcetris, has r
Drug Discovery
Bothell, WA
1,605 As of 2019
00.000
000000000 00.000

00000000

re eu fugiat nulla pariatur. Excepteur sint occaecat cupidatat non proident, sunt in culpa qui offic
0000 000000000
Alameda, CA
000 As of 0000
00000
0&0

00000

amco laboris nisi ut aliquip ex ea commodo consequat. Duis aute irure dolor in reprehenderit in volu
0000000000000
Cambridge, MA
000 As of 0000
00000
000000&0
Add Comparison

PitchBook’s comparison feature gives you a side-by-side look at key metrics for similar companies. Personalize which data points you want to see and create visualizations instantly.

Request a free trial

Seattle Genetics Competitors (50)

Company Name Financing Status Location Employees Total Raised Last Financing Date/Type Last Financing Amount
Exelixis Formerly VC-backed Alameda, CA 000 00000 0&0
00000 Formerly VC-backed Cambridge, MA 000 00000 000000&0
000000 Formerly VC-backed Monrovia, CA 000 00000 00000000 00000
000000 00000000000 Formerly VC-backed San Francisco, CA 000 00.000 000000000 00.000
000000000 Formerly VC-backed Waltham, MA 00 00000 00000000 00000
You’re viewing 5 of 50 competitors. Get the full list »

Seattle Genetics Executive Team (13)

Name Title Board Seat Contact Info
Clay Siegall Ph.D Co-Founder, President, Chief Executive Officer & Chairman of the Board
Todd Simpson Chief Financial Officer
Vaughn Himes Ph.D Chief Technology Officer, Technology
Matt Onsum Ph.D Senior Director Translational Science, Head of Diagnostics, Bioinformatics, and Biomarkers
Jean Liu JD Executive Vice President & General Counsel, Legal
You’re viewing 5 of 13 executive team members. Get the full list »

Seattle Genetics Board Members (11)

Name Representing Role Since
Clay Siegall Ph.D Seattle Genetics Co-Founder, President, Chief Executive Officer & Chairman of the Board 000 0000
Daniel Welch Self Board Member 000 0000
David Gryska Self Board Member 000 0000
Felix Baker Ph.D Baker Bros. Advisors Board Member 000 0000
John Orwin Self Board Member 000 0000
You’re viewing 5 of 11 board members. Get the full list »

Seattle Genetics Signals

Growth Rate

0.80% Weekly
Growth
Weekly Growth 0.80%, 93rd %ile
-35.5%. 530%

Size Multiple

219x Median
Size Multiple 219x, 100th %ile
0.00x 0.95x. 413Kx

Key Data Points

Twitter Followers

5.5k

Similarweb Unique Visitors

15.0K

Majestic Referring Domains

314

PitchBook’s non-financial metrics help you gauge a company’s traction and growth using web presence and social reach.

Request a free trial

Seattle Genetics Investments & Acquisitions (4)

Company Name Deal Date Deal Type Deal Size Industry Lead Partner
000000000 00000000 01-Mar-2018 000000000000000000 00000 Biotechnology 0000 0000000 00.0
0000000-00000 0000 01-Oct-2017 000000000 00000 00 000.00 Buildings and Property 0000 0000000 00.0
00000 00000 000000 01-Aug-2017 000000000000000000 000.00 Laboratory Services (Healthcare) 000000 00000 00.0
Cogent Biosciences 11-Jun-2015 Early Stage VC 0000 Biotechnology 0000 0000000 00.0
To view Seattle Genetics’s complete investments and acquisitions history, request access »

Seattle Genetics Exits (1)

Company Name Exit Date Exit Type Exit Size Status Buyers
000000 00000000000 11-Jun-2015 00000 00000 00 0000 Completed
  • 14 buyers
To view Seattle Genetics’s complete exits history, request access »